Literature DB >> 17420808

Bivalirudin anticoagulation for cardiopulmonary bypass: an unusual case.

Nicolas Nikolaidis1, Theodore Velissaris, Sunil K Ohri.   

Abstract

The standard agent used for systemic anticoagulation during cardiopulmonary bypass is heparin. Alternative methods of anticoagulation are required for patients with heparin hypersensitivity. We present the case of a patient with heparin hypersensitivity who was anticoagulated with bivalirudin during cardiopulmonary bypass for coronary artery bypass grafting. This presented unusual challenges surrounding the monitoring of anticoagulation and the method of myocardial protection.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17420808      PMCID： PMC1847925     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN： 0730-2347


  13 in total

Review 1.  The use of bivalirudin in patients with renal impairment.

Authors:  R Robson
Journal:  J Invasive Cardiol       Date:  2000-12       Impact factor: 2.022

2.  Recombinant hirudin as anticoagulant during cardiopulmonary bypass.

Authors:  F C Riess; J Kormann; B Poetzsch
Journal:  Anesthesiology       Date:  2000-12       Impact factor: 7.892

Review 3.  Heparin-associated thrombocytopenia and thrombosis: optimal therapy with ancrod.

Authors:  C W Cole; L M Fournier; J Bormanis
Journal:  Can J Surg       Date:  1990-06       Impact factor: 2.089

4.  The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction.

Authors:  S K Swan; M J Hursting
Journal:  Pharmacotherapy       Date:  2000-03       Impact factor: 4.705

5.  Tolerance to intravenous heparin in patients with delayed-type hypersensitivity to heparins: a prospective study.

Authors:  Zeno Gaigl; Petra Pfeuffer; Petra Raith; Eva-B Bröcker; Axel Trautmann
Journal:  Br J Haematol       Date:  2005-02       Impact factor: 6.998

6.  Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases.

Authors:  P Fernandes; R Mayer; J L MacDonald; A G Cleland; C Hay-McKay
Journal:  Perfusion       Date:  2000-11       Impact factor: 1.972

7.  Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban.

Authors:  A Koster; M Kukucka; F Bach; O Meyer; T Fischer; F Mertzlufft; M Loebe; R Hetzer; H Kuppe
Journal:  Anesthesiology       Date:  2001-02       Impact factor: 7.892

8.  Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery.

Authors:  Julio C Vasquez; Anna Vichiendilokkul; Syed Mahmood; Frank A Baciewicz
Journal:  Ann Thorac Surg       Date:  2002-12       Impact factor: 4.330

9.  Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia.

Authors:  C Demers; J S Ginsberg; P Brill-Edwards; A Panju; T E Warkentin; D R Anderson; C Turner; J G Kelton
Journal:  Blood       Date:  1991-11-01       Impact factor: 22.113

10.  Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases.

Authors:  U Jappe; U Juschka; N Kuner; B M Hausen; K Krohn
Journal:  Contact Dermatitis       Date:  2004-08       Impact factor: 6.600
View more
  2 in total

1.  Bivalirudin as an Alternative Anticoagulant for Cardiopulmonary Bypass During Adult Cardiac Surgery-A Change in Practice.

Authors:  Peter Gatt; Samuel Anthony Galea; Walter Busuttil; Charles Grima; Jeffrey Muscat; Yvette Farrugia
Journal:  J Extra Corpor Technol       Date:  2017-03

2.  An Anti-Coagulation Conundrum: Implantation of Total Artificial Heart in a Patient with Heparin-Induced Thrombocytopenia Type II.

Authors:  Theodore J Cios; Yuliana Salamanca-Padilla; Dmitri Guvakov
Journal:  Am J Case Rep       Date:  2017-03-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.